Navigation Links
Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
Date:3/4/2008

-that were statistically significant for at least two of the four linaclotide dose groups for each endpoint. Linaclotide was well tolerated at all doses with no serious adverse events in any patient during the treatment period. The most common adverse event was diarrhea, which was dose-related and ranged from 4.8 percent to 14.3 percent in the linaclotide-treated patients compared to 2.9 percent of placebo-treated patients. Diarrhea resulted in discontinuation of 2.5 percent of linaclotide-treated patients and no placebo-treated patients. At this time the companies have reviewed only top-line results and further analyses will be conducted in the coming weeks.

An interim analysis of the recently completed 12-week IBS-C study was carried out to enable timely dose selection for Phase 3 trials. The interim analysis was performed on the unlocked database for this study, following the last patient's last visit. Patients with IBS-C who received once-daily treatment with linaclotide experienced a significant increase in weekly CSBM frequency rate-the primary endpoint for this study-at all doses except for 150 mcg. Linaclotide-treated patients also experienced improvements in all other top-line efficacy endpoints-SBM frequency, stool consistency, abdominal pain, bloating, abdominal discomfort, adequate relief, and IBS-C symptom severity-that were statistically significant for at least two of the four linaclotide dose groups for each endpoint. Linaclotide was well tolerated at all doses; there was one serious adverse event in a linaclotide-treated patient which was considered unrelated to treatment by the investigator. The most common adverse event was diarrhea, and diarrhea was the most common adverse event resulting in discontinuation. Once the full analysis of the data is completed, Microbia and Forest Laboratories plan to present the results of these trials at an appropriate scientific conference.

Based on these data and subject to a complete review of the f
'/>"/>

SOURCE Microbia, Inc. and Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Congressional Funds Awarded for Testing of Antimicrobial Copper Metals
2. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. D1 Sports Training Facilities Adopt TurfAide(TM) Antimicrobial to New Synthetic Turf Fields from AstroTurf(R)
4. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
5. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
6. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. Federal Funding Awarded to Test Antimicrobial Properties of Copper Metals
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... Report Details Ovarian Cancer ... Changes and Emerging Opportunities What,s the future for ... study forecasts those pharmaceutical revenues. There you find ... also explore trends, results, treatments, R&D, and opportunities, ... predictions to 2025 at overall world market, submarket, ...
(Date:9/3/2015)... Sept. 3, 2015 With a population of ... country and therefore also its single largest potential market ... China has led all major world economies in the ... expenditures, and government health expenditures. As an in vitro ... markets of the United States, western European countries, and ...
(Date:9/3/2015)... 2015 About artificial organs ... are implanted or integrated into individuals to ... artificial heart, kidney, pancreas, and cochlear implants. ... and porous polypropylene), biologics, ceramics, and metals ... organs are incorporated with different technologies like ...
Breaking Medicine Technology:Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6IVD in China 2IVD in China 3IVD in China 4IVD in China 5IVD in China 6IVD in China 7IVD in China 8IVD in China 9IVD in China 10IVD in China 11IVD in China 12IVD in China 13Global Artificial Organ Market 2015-2019 2
... Scientific Corporation (NYSE: BSX ) today ... OMEGA™ Platinum Chromium Bare-Metal Coronary Stent System, the ... Scientific,s unique platinum chromium (PtCr) alloy designed specifically ... interventional cardiologists with a bare-metal stent with improved ...
... Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS ... at Cowen and Company,s 31st Annual Health Care Conference being ... Shortall, Chief Executive Officer of Unilife, is scheduled to present ... The conference presentation will be broadcast over the Internet ...
Cached Medicine Technology:Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 2Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 3Boston Scientific Announces European Approval and Launch of OMEGA™ Platinum Chromium Stent System 4Unilife to Present at the 31st Annual Cowen Health Care Conference on Wednesday, March 9, 2011 in Boston 2
(Date:9/4/2015)... ... September 04, 2015 , ... ... surrounding communities, is launching a charity effort to provide for the family of ... as an enlarged heart, restrictive cardiomyopathy often leads to diastolic dysfunction – the ...
(Date:9/4/2015)... ... September 04, 2015 , ... A Union County charitable ... Core Compassion Project is a non-profit organization dedicated to offering Pilates scholarships to ... cancer treatments and recover their mobility, strength, and range of motion following breast ...
(Date:9/4/2015)... San Francisco, CA (PRWEB) , ... September 04, ... ... Ben Amini, announces that CEREC technology is now available at CitiDent. CEREC is ... milling machinery. In addition to saving time for patients by eliminating the need ...
(Date:9/4/2015)... ... September 04, 2015 , ... Many consumers are looking for a quick and convenient way to ... The patent-pending K Med Cups provide a quick and simple way to brew a hot ... flu or cough. As a result, they enhance comfort and health. The invention features a ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
Breaking Medicine News(10 mins):Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 2Health News:Georgia Insurance Advisors Inaugurates Charity Drive to Assist the Family of Young Local Girl Diagnosed with an Enlarged Heart 3Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Redesigned Packaging for Powdered Medicinal Mix Invented by InventHelp® Client (CBA-2637) 2Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... New findings published in the Annals of Internal Medicine ... patients who are on the verge of kidney failure ... Health Research Institute scientists in London, Canada found that ... myeloma has no benefits. ,This means that ...
... down under states that Vitamin D known for its bone ... has been found to be a boon for respiratory functions. ... for smokers, asthmatics and other people with respiratory problems. ... in their systems showed better lung function than those with ...
... Prevention and Control (ECDC) based in Stockholm has proposed ... to the avian flu. //Approval has been granted to ... ,The guidelines are inclusive of controlling infection of birds ... that are infected should also be minimized according to ...
... from bird flu, increasing the risk of human infection in ... ,Swabs from a 35-year-old man who died in Jakarta last ... a World Health Organization reference laboratory, Health Ministry officials said ... of bird flu in the world's fourth most-populous nation to ...
... treated with 500 mcg of Aranesp (Darbepoetin alfa) for ... in 70% of patients. //The new drug Aranesp is ... trial with 200 low-risk MDS patients who were administered ... is a pre-leukemia stage in which the bone marrow ...
... hailed as a wonder drug that can take care of ... emerged that it can also induce cancer cells to commit ... in the December 9 issue of the Journal of Biological ... cells in combination with a new therapy called as tumor ...
Cached Medicine News:Health News:Indonesia Has Ninth Bird-Flu Death as Risk Mounts 2Health News:Aspirin induces Cancer Cells To Commit Suicide 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: